Evidence map›Paper›PMID 41174475›Full record

ArticleCellular & molecular biology letters2025

MicroRNA strand ratio disarray promotes temozolomide resistance in glioblastoma.

Fangfang Shen, Pengfei Wu, Zelian Li, Minglong Yang, Zhuolun Li, Yunfeng Nan, Qinglin Yang, Yuanfei Wang, Xuedong Li, Ying Ye and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fangfang Shen *Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230027, Anhui, China.
Pengfei Wu *Department of Neurosurgery, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China. wupengfei@ustc.edu.cn.
Zelian LiDepartment of Obstetrics and Gynecology, The First Affiliated Hospital, Anhui Medical University, Hefei, 230020, Anhui, China.
Minglong YangDepartment of Neurosurgery, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Zhuolun LiDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Yunfeng NanDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China.
Qinglin YangAnhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Anhui, 233030, China.
Yuanfei WangDepartment of Neurosurgery, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China.
Xuedong LiDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. h06370@hrbmu.edu.cn.
Ying YeDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230027, Anhui, China. yeying2@139.com.
Jinpeng WangDepartment of Urology, The Second Affiliated Hospital of Harbin Medical University, Harbin, 150086, China. wjp19970630@163.com.

Funding

2022 Anhui Province Postdoctoral Researchers' Scientific Research Activity Funding Project 2022B580Open Project of Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment KFKT202401the China Postdoctoral Science Foundation 2022TQ0326the China Postdoctoral Science Foundation 2023M733391the National Natural Science Foundation of China 82202868the National Natural Science Foundation of China 82573367the Natural Science Foundation of Anhui Province 2208085QH251
6 · The paper itself

Abstract

backgroundDisarray in microRNA (miRNA) strand selection is associated with multiple tumors. However, the mechanisms underlying miRNA strand selection-driven temozolomide (TMZ) resistance in glioblastoma (GBM) remain unexplored. APPROACH AND

resultsHere, we observed that the strand selection disarray of miR-92b contributes to enhancing TMZ resistance. The pattern of higher expression of miR-92b-3p and lower expression of miR-92b-5p is significantly correlated with TMZ resistance. In TMZ-resistant GBM cells, miR-92b-3p and miR-92b-5p increased the enrichment of H3K27ac in the COL7A1 promoter region by divergently targeting HDAC9 and FOXP3, thereby elevating COL7A1 expression and mediating collagen deposition. In addition, TUT4 regulated strand selection of pre-miR-92b through uridylation, promoting preference for the 3' strand (3p). The TUT4 inhibitor aurothioglucose hydrate (ATG-H) blocked the miR-92b strand selection disarray and restored TMZ sensitivity in TMZ-resistant GBM cells.

conclusionsOur study demonstrates that TUT4-mediated elevation of the miR-92b-3p/-5p ratio promotes COL7A1 transcription via silencing HDAC9 and alleviation of FOXP3 targeting, leading to collagen deposition and heightened TMZ resistance. Our results suggest that targeting miR-92b strand selection may serve as a potential therapeutic strategy for sensitizing GBM to TMZ.

Indexed as

Brain NeoplasmsDrug Resistance, NeoplasmGlioblastomaMicroRNAsTemozolomideAntineoplastic Agents, AlkylatingCell Line, TumorForkhead Transcription FactorsGene Expression Regulation, NeoplasticHistone DeacetylasesHumansRepressor ProteinsAntineoplastic Agents, AlkylatingForkhead Transcription FactorsFOXP3 protein, humanHDAC9 protein, humanHistone DeacetylasesMicroRNAsMIRN92 microRNA, humanRepressor ProteinsTemozolomideGlioblastomamicroRNAStrand selectionTemozolomide resistanceUridylation

Identifiers

PMID41174475
PMCPMC12577214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.